sb 203580 has been researched along with bibw 2992 in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (bibw 2992) | Trials (bibw 2992) | Recent Studies (post-2010) (bibw 2992) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 1,044 | 147 | 1,007 |
Protein | Taxonomy | sb 203580 (IC50) | bibw 2992 (IC50) |
---|---|---|---|
Epidermal growth factor receptor | Homo sapiens (human) | 0.0361 | |
Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0168 | |
Cytochrome P450 1A2 | Homo sapiens (human) | 0.037 | |
Cytochrome P450 2E1 | Homo sapiens (human) | 0.014 | |
Cytochrome P450 2C8 | Homo sapiens (human) | 0.037 | |
Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0007 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 0.037 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.0016 | |
Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0024 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
1 other study(ies) available for sb 203580 and bibw 2992
Article | Year |
---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |